Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients

Pfizer

Status: Completed

Conditions: HIV-1 Infection

Treatments: Drug: Rescriptor

Study type: Observational

Funder types: Industry

Identifiers

NCT00823966

A4351010

Details and patient eligibility

About

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Local Product Document (LPD) (unlisted adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Full description

All the patients whom an investigator prescribes the first Rescriptor® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Enrollment: 3 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients need to be administered Rescriptor® in order to be enrolled in the surveillance.

Exclusion criteria

Patients not administered Rescriptor®.

Trial design

3 participants in 1 patient group

Delavirdine Mesilate

Description:

Patients administered.

Treatment:

Drug: Rescriptor